Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22527749 | 1.00 | ALDH1A1 (0.38) | ALDH1A1USP2LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL30568148 | 0.89 | ALDH1A1 (0.39) | ALDH1A1USP2LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL29555497 | 0.89 | ALDH1A1 (0.39) | ALDH1A1USP2LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL24329817 | 0.89 | ALDH1A1 (0.39) | ALDH1A1USP2LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL30966733 | 0.85 | HPGD (0.36) | ALDH1A1USP2LMNAKMT2AMAPT | |
| SCHEMBL27255582 | 0.85 | HPGD (0.36) | ALDH1A1USP2LMNAKMT2AMAPT | |
| SCHEMBL30966736 | 0.82 | MAPT (0.32) | ALDH1A1LMNAKMT2AMAPTMEN1 | |
| SCHEMBL27255597 | 0.82 | MAPT (0.32) | ALDH1A1LMNAKMT2AMAPTMEN1 | |
| SCHEMBL22527795 | 0.81 | HTT (0.35) | ALDH1A1USP2LMNASMN1; SMN2MAPT | |
| SCHEMBL30029235 | 0.80 | HPGD (0.38) | ALDH1A1USP2LMNAKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042883-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2025-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042883-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | ALDH1A1 626/4885USP2 3860/4885LMNA 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.